

## Claims

1. A binding agent comprising:  
a CDR-L1, a CDR-L2 and a CDR-L3 which are three polypeptide sequences of  
5 a light chain complementarity determining region (CDR-L),  
wherein the CDR-L1 is selected from SEQ ID Nos 1-15, the CDR-L2 is selected  
from SEQ ID Nos 16-25 and the CDR-L3 is selected from SEQ ID Nos 26-36, and  
wherein the binding agent specifically binds to an extracellular domain of  
mesenchymal epithelial transition factor (cMET).
- 10 2. A binding agent comprising:  
a CDR-H1, a CDR-H2 and a CDR-H3 which are three polypeptide sequences of  
a heavy chain complementarity determining region (CDR-H),  
wherein the CDR-H1 is selected from SEQ ID Nos 50-61, the CDR-H2 is  
15 selected from SEQ ID Nos 62-78 and the CDR-H3 is selected from SEQ ID Nos 79-93,  
and  
wherein the binding agent specifically binds to an extracellular domain of  
mesenchymal epithelial transition factor (cMET).
- 20 3. A binding agent comprising:  
a CDR-L1 selected from SEQ ID NOs. 1-15, a CDR-L2 selected from SEQ ID  
NOs. 16-25, a CDR-L3 selected from SEQ ID NOs. 26-36, a CDR-H1 selected from  
SEQ ID Nos 50-61, a CDR-H2 selected from SEQ ID Nos 62-78, and a CDR-H3  
selected from SEQ ID Nos 79-93  
25 wherein the binding agent specifically binds to an extracellular domain of  
mesenchymal epithelial transition factor (cMET).
4. The binding agent of claim 1 or 3, wherein the CDR-L1 is selected from  
SEQ ID NOs 2, 4, 6, 8, 9, 10, 12, 14 and 15.
- 30 5. The binding agent of claim 1, 3 or 4, wherein the CDR-L2 is selected  
from SEQ ID NOs 17, 19, 21, 23, 24 and 25.

6. The binding agent of claim 1, 3, 4 or 5, wherein the CDR-L3 is selected from SEQ ID NOs 27, 29, 31, 33, 34 and 35.

5 7. The binding agent of claim 2 or 3, wherein the CDR-H1 is selected from SEQ ID NOs 51, 53, 55, 57, 58 and 59.

8. The binding agent of claim 2, 3 or 7, wherein the CDR-H2 selected from SEQ ID Nos 62-78 is selected from SEQ ID NOs 63, 65, 67, 69, 70, 71, 73, 75 and 78.

10

9. The binding agent of claim 2, 3 or 8, wherein the CDR-H3 is selected from SEQ ID NOs 80, 82, 84, 86, 87, 88, 91 and 93.

10. The binding agent of any one of claims 1 to 9, wherein the CDR-L1 is  
15 SEQ ID NO 9 or 10, CDR-L2 is SEQ ID NO 24 or 25, the CDR-L3 is SEQ ID NO 34 or 35, CDR-H1 is SEQ ID NO 58 or 59, CDR-H2 is SEQ ID NO 70 or 71, and CDR-H3 is SEQ ID NO 87 or 88.

11. The binding agent of any one of claims 1 to 10, wherein the binding  
20 agent is an antibody, or a binding fragment thereof.

12. The binding agent of any one of claims 1 to 11, wherein the binding agent comprises a variable light chain region having an amino acid sequence selected from SEQ ID NOS 37-44.

25

13. The binding agent of any one of claims 1 to 11, wherein the binding agent comprises a variable heavy chain region having an amino acid sequence selected from SEQ ID NOS 94-103.

14. The binding agent of any one of claims 1 to 11, wherein the binding agent comprises a light chain sequence selected from SEQ ID NOS 46-49.

30

15. The binding agent of any one of claims 1 to 11, wherein the binding agent comprises a heavy chain sequence selected from SEQ ID NOS 105-108.

16. The binding agent of claim 14 or 15, wherein the light chain sequence  
5 selected from SEQ ID NOS 46-49 and/or the heavy chain sequence selected from SEQ ID NOS 105-108 comprises one to five amino acid modifications selected from an amino acid addition, an amino acid deletion and an amino acid substitution.

17. The binding agent of claim 16, wherein the light chain sequence  
10 comprises SEQ ID NO 47 and the heavy chain sequence comprises SEQ ID NO 108.

18. The binding agent of any one of claims 1 to 17, wherein the binding agent induces internalization of cMET on a human cancer cell.

19. The binding agent of any one of claims 1 to 17, wherein the binding agent induces degradation of cMET on a human cancer cell.

20. The binding agent of any one of claims 1 to 19, wherein the binding agent comprises an anti-neoplastic agent.

20

21. A composition comprising a first binding agent that is the binding agent of any one of claims 1 to 19, and a second binding agent that does not bind specifically to cMET.

22. The composition of claim 21, wherein the first binding agent is the binding agent that specifically binds to the extracellular domain of cMET and the second binding agent is conjugated to the first binding agent.

23. The binding agent of any one of claims 1 to 20 or the composition of  
30 claim 21 or 22 for use in treating a subject having a neoplastic disorder or cancer.

24. The binding agent or the composition for use of claim 23, wherein the

binding agent specifically binds to the extracellular domain of cMET expressed on one or more cells of the subject.

25. The binding agent or the composition for use of claim 23 or 24, wherein  
5 the binding agent inhibits mitosis of, and/or induces death of the one or more cells expressing cMET.

26. The binding agent or the composition for use of any one of claims 23 to  
25, wherein the neoplastic disorder or cancer comprises a lung carcinoma, breast  
10 carcinoma, ovarian carcinoma, kidney carcinoma, colorectal carcinoma, gastric carcinoma, thyroid carcinoma, pancreas carcinoma, neuroblastoma, or a squamous cell carcinoma of the head and neck, cervical cancer, hepatocellular cancer, sarcomas, mesothelioma, glioblastoma, multiple myeloma, melanoma, prostate and esophageal carcinoma.

15

27. Use of a therapeutically effective amount of the binding agent of any one of claims 1 to 20 or the composition of claim 21 or 22 in the manufacture of a medicament for treating a subject having a neoplastic disorder or cancer.

20 28. The use of claim 27, wherein the binding agent specifically binds to the extracellular domain of cMET expressed on one or more cells of the subject.

29. The use of claim 27 or 28, wherein the binding agent inhibits mitosis of, and/or induces death of the one or more cells expressing cMET.

25

30. The use of any one of claims 27 to 29, wherein the neoplastic disorder or cancer comprises a lung carcinoma, breast carcinoma, ovarian carcinoma, kidney carcinoma, colorectal carcinoma, gastric carcinoma, thyroid carcinoma, pancreas carcinoma, neuroblastoma, or a squamous cell carcinoma of the head and neck, cervical  
30 cancer, hepatocellular cancer, sarcomas, mesothelioma, glioblastoma, multiple myeloma, melanoma, prostate and esophageal carcinoma.

31. A pharmaceutical composition comprising the binding agent of any one of claims 1 to 20, and a pharmaceutically acceptable excipient, diluent, additive or carrier.